Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Jun 3, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

ASCO Updates Value Framework 

 

The American Society of Clinical Oncology published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials.

The framework defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms or quality of life in the context of cost. The updated framework will be the basis for a software tool that doctors can use to assist shared decision-making with their patients. The update was published in the Journal of Clinical Oncology.

ASCO modified the Net Health Benefit score, the weighted measure of a treatment’s benefits and side effects, to better reflect differences between treatments: to calculate the efficacy of a treatment, the framework now uses hazard ratios, when available, rather than absolute survival measures. The framework also recognizes treatments that improve long-term disease control for a significant portion of patients, according to ASCO.

Additionally, the framework now considers all side effects in the Net Health Benefit score, not just the most severe, high-grade toxicities. This change reflects feedback from patients who emphasized that even mild side effects can have a major impact on quality of life.

The revised framework will continue to only evaluate treatments that were studied head-to-head in prospective randomized clinical trials, said ASCO President Julie Vose in a statement.

“Some commenters expressed interest in making cross-trial comparisons, and ASCO agrees such comparisons would be valuable,” Vose said. “However, head-to-head trials remain the only scientifically valid way to compare two treatments, given differences in trial designs, patient populations, cancer stages, and other factors. In addition, the framework will continue to focus on cancer drugs, rather than other interventions.”



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter